Opendata, web and dolomites

CylcoRu4PACT TERMINATED

Cyclometallated ruthenium complexes for photo-activated chemotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CylcoRu4PACT project word cloud

Explore the words cloud of the CylcoRu4PACT project. It provides you a very rough idea of what is the project "CylcoRu4PACT" about.

cell    photochemotherapeutic    alternative    compounds    vitro    synthesize    absorption    hindering    keeping    carbon    window    photodynamic    model    modifies    tumours    cyclometallation    overcome    concentration    polypyridyl    fails    maximizing    curing    anticancer    prodrugs    ligand    locally    excited    toxicity    cytotoxicity    place    synthesized    light    chemotherapy    minimizing    tissues    human    biological    metal    shift    hard    lines    hypoxic    concentrations    red    grounds    optimally    efficacy    cancer    ruthenium    stand    therapy    bond    containing    dark    limit    patient    efficient    penetrates    irradiation    determined    wavelength    photosubstitution    occurring    groups    tumour    usually    wavelengths    phototherapy    quenches    treatment    sterically    measured    photochemical    clinic    chemotherapeutic    introduce    compound    visible    sensitive    too    energy    reactions    consist    photoreactivity    complexes    treatments    released    cyclometallated    recover    oxygen   

Project "CylcoRu4PACT" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT LEIDEN 

Organization address
address: RAPENBURG 70
city: LEIDEN
postcode: 2311 EZ
website: www.universiteitleiden.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.universiteitleiden.nl/en/staffmembers/sylvestre-bonnet
 Total cost 165˙598 €
 EC max contribution 165˙598 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT LEIDEN NL (LEIDEN) coordinator 165˙598.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Chemotherapy is efficient in curing cancer, but most treatments are very hard to stand for the patient, and side effects limit treatment efficacy. Phototherapy is a promising alternative, where the toxicity of a light-sensitive chemotherapeutic compound is locally released upon visible light irradiation of the compound-containing tumour. Photodynamic therapy is already available in the clinic for oxygen-rich tumours; however, it fails when the oxygen concentration at the place of irradiation is too low. In this project I propose to synthesize new ruthenium-based photochemotherapeutic compounds containing cyclometallated ligand, and to test them in an in vitro model of hypoxic cancer. The presence of a carbon-metal bond is known to shift the light absorption properties of ruthenium polypyridyl complexes towards the photodynamic window, a wavelength range where light penetrates optimally into biological tissues. However, cyclometallation usually quenches the ligand photosubstitution properties of ruthenium compounds because it strongly modifies the energy of their excited states. In this project, I will introduce sterically hindering groups on the cyclometallated ligand to recover photoreactivity of the complexes while keeping light absorption at high wavelengths. The challenges of this project consist on the one hand in achieving efficient ligand photosubstitution reactions with cyclometallated ruthenium compounds, and on the other hand in minimizing the cytotoxicity in the dark while maximizing cytotoxicity after red light irradiation at low oxygen concentrations. The ruthenium prodrugs will be synthesized, their photochemical properties will be measured, and their cytotoxicity against human cancer cell lines will be determined in an in vitro model of hypoxic cancer. This project will set new grounds in the treatment of hypoxic tumours and propose a new way to overcome side effects occurring in traditional anticancer chemotherapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CYLCORU4PACT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CYLCORU4PACT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

TCFLAND2SEA (2020)

Thawing Carbon From LAND to SEA: Microbial Degradation of Organic Matter and Response to Thawing Permafrost in the Northeast Siberian Land-Shelf System

Read More  

AsymmFlow (2020)

Go with the continuous flow: Asymmetric Synthesis of Bioactive Alkaloids by Multistep Continuous-Flow Processes

Read More